Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Daniel Van Aartsen"'
Autor:
Prakruti Rao, Svetlana Zhdanova, Oleg Ogarkov, Elizaveta Orlova, Andrew Ebers, Suzanne Stroup, Shino Mirawdaly, Daniel Van Aartsen, Olga Koshkina, Alexey Suzdalnitsky, Elena Moiseeva, Rebecca Dillingham, Scott K Heysell
Publikováno v:
International Journal of Mycobacteriology, Vol 9, Iss 4, Pp 411-416 (2020)
Background: Levofloxacin is a preferred drug for multidrug-resistant (MDR)-tuberculosis (TB) with bactericidal activity that correlates with the pharmacokinetic exposures of serum peak concentration (Cmax) and total area under the concentration time
Externí odkaz:
https://doaj.org/article/c4cc1be307334b3a8c61b6cdbe2f046e
Autor:
Daniel, Van Aartsen, Museveni, Justine, Estomih, Mduma, Stellah G, Mpagama, Mohammad H, Alshaer, Charles A, Peloquin, Buliga, Mujaga, Athanasia, Maro, Jean, Gratz, Margaret, Kosek, Jie, Liu, Elizabeth T, Rogawski McQuade, Eric R, Houpt, Tania A, Thomas, Scott K, Heysell
Publikováno v:
The Lancet Microbe. 3:e408-e416
Enteropathy is prevalent in tuberculosis-endemic areas, and it has been shown to impair intestinal absorptive function; therefore, enteropathogen burden might negatively affect antimycobacterial pharmacokinetics, particularly among malnourished child
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed46ad4653881319718923a98b1c03e
https://doi.org/10.1016/s2666-5247(21)00308-6
https://doi.org/10.1016/s2666-5247(21)00308-6
Autor:
Pranay Sinha, Scott K. Heysell, Padmini Salgame, William E. Rudgard, Daniel Van Aartsen, Delia Boccia, Natasha S. Hochberg, Sonali Sarkar, Knut Lönnroth, Anurag Bhargava
Publikováno v:
The Lancet Infectious Diseases. 21:e318-e325
Tuberculosis is the leading cause of deaths from an infectious disease worldwide. WHO's End TB Strategy is falling short of several 2020 targets. Undernutrition is the leading population-level risk factor for tuberculosis. Studies have consistently f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2593897d6f8dfee2a1921d65c6ae8569
https://doi.org/10.1016/s1473-3099(20)30792-1
https://doi.org/10.1016/s1473-3099(20)30792-1
Autor:
Heba Alhmidi, Daniel Van Aartsen, Curtis J. Donskey, Amrita John, Jennifer L. Cadnum, Manish Thakur
Publikováno v:
American Journal of Infection Control. 50:220-222
In an observational study, the sleeves and pockets of physicians' white coats often directly or indirectly contacted patients and environmental surfaces. DNA markers on the sleeves or pockets were frequently transferred to surfaces and patients. Thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69fdc912e817bf4c81cf19239a7076e5
https://doi.org/10.1016/j.ajic.2021.10.016
https://doi.org/10.1016/j.ajic.2021.10.016
Autor:
Museveni Justine, Mohammad H. Al-Shaer, Tania A Thomas, Charles A. Peloquin, Sarah Criddle, Christopher Vinnard, Stellah G. Mpagama, Estomih Mduma, Scott K. Heysell, Daniel Van Aartsen, Isaac Zentner, Prakruti Rao, Claire Szipszky
Publikováno v:
J Pediatric Infect Dis Soc
Background Individual pharmacokinetic variability is a driver of poor tuberculosis (TB) treatment outcomes. We developed a method for measurement of rifampin concentrations by urine colorimetry and a mobile phone photographic application to predict c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26ea77a08b6cc13d73a719c4ff978b37
https://doi.org/10.1093/jpids/piaa024
https://doi.org/10.1093/jpids/piaa024
Autor:
Daniel Van Aartsen, Christopher S. Eickhoff, Anne S. De Groot, Isaac G. Sakala, Krystal A. Meza, Leonard Moise, William D. Martin, Linda Peng, Daniel F. Hoft, R. Mark L. Buller, Jill Schriewer, Frances Terry
Publikováno v:
Vaccine
Influenza world-wide causes significant morbidity and mortality annually, and more severe pandemics when novel strains evolve to which humans are immunologically naïve. Because of the high viral mutation rate, new vaccines must be generated based on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b26f3a7285dde6f725dc8d5f8402583
https://pubmed.ncbi.nlm.nih.gov/31331771
https://pubmed.ncbi.nlm.nih.gov/31331771
Autor:
Elizaveta Orlova, Rebecca Dillingham, Elena P. Moiseeva, Daniel Van Aartsen, Alexey Suzdalnitsky, Svetlana Zhdanova, Shino Mirawdaly, Andrew Ebers, Scott K. Heysell, Oleg Ogarkov, Olga Koshkina, Suzanne Stroup, Prakruti Rao
Publikováno v:
International journal of mycobacteriology
International Journal of Mycobacteriology, Vol 9, Iss 4, Pp 411-416 (2020)
International Journal of Mycobacteriology, Vol 9, Iss 4, Pp 411-416 (2020)
Background Levofloxacin is a preferred drug for multidrug-resistant (MDR)-tuberculosis (TB) with bactericidal activity that correlates with the pharmacokinetic exposures of serum peak concentration (Cmax) and total area under the concentration time c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a9a2b5e253cd85a7842907d2f90bd26
https://doi.org/10.4103/ijmy.ijmy_186_20
https://doi.org/10.4103/ijmy.ijmy_186_20
Autor:
Khalid M, Dousa, Ahmed, Babiker, Daniel, Van Aartsen, Neel, Shah, Robert A, Bonomo, John L, Johnson, Marion J, Skalweit
Publikováno v:
Open Forum Infectious Diseases
Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first cas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::392f196654ad541c2145c28c53b220b8
https://pubmed.ncbi.nlm.nih.gov/30090839
https://pubmed.ncbi.nlm.nih.gov/30090839
Autor:
Ahmed Babiker, Neel B Shah, Robert A. Bonomo, Khalid M Dousa, John L. Johnson, Marion J. Skalweit, Daniel Van Aartsen
Publikováno v:
Open Forum Infectious Diseases. 5
Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first cas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5424aca4247bc250d1d82b7fd69a63e3
https://doi.org/10.1093/ofid/ofy168
https://doi.org/10.1093/ofid/ofy168
Autor:
Daniel Van Aartsen, Mahmoud M. Traina, Frances Terry, Sheba Meymandi, Annie De Groot, Leonard Moise, Christopher S. Eickhoff, Salvador Hernandez, Daniel F. Hoft, William D. Martin
Publikováno v:
Human Vaccines & Immunotherapeutics. 11:2322-2328
Chagas disease is a major neglected tropical disease caused by persistent chronic infection with the protozoan parasite Trypanosoma cruzi. An estimated 8 million people are infected with T. cruzi, however only 2 drugs are approved for treatment and n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59c3f8707004ea27f341852791a2edcc
https://doi.org/10.1080/21645515.2015.1061160
https://doi.org/10.1080/21645515.2015.1061160